Alongside its agenda for regulatory reform this week, BIO will roll out a series of proposals for tax law and other financial legislation to bolster biotech capital formation.

Although BIO is working with members of Congress to have its capital formation proposals introduced as part of broader legislation that would include its regulatory innovation platform, the tax and finance elements will have to be enacted separately, probably as part of tax reform initiatives (see "Progressive Thinking for FDA," A12).